The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and Truqap ahead ...
AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a phase 2 study. The U.K.-based pharma had been evaluating the antisense ...
The coronavirus vaccine developed by AstraZeneca (NASDAQ: AZN) in partnership with Oxford University has succeeded in preventing transmission of COVID-19. Unfortunately, a disappointing series of ...
(Reuters) -AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 billion investment to expand there, as President Donald Trump ...
LONDON, Feb 10 (Reuters) - AstraZeneca forecast steady profit growth in 2026 on Tuesday, banking on strong demand for cancer drugs and new launches to offset patent losses and pricing pressure as ...
AstraZeneca's CEO told daily Handelsblatt on Tuesday that Germany risks missing out on new drugs that the Anglo-Swedish drugmaker plans to launch if the nation sticks with plans to keep spending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results